Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL27727092 | 0.97 | TSHR (0.39) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Pyrrolidine SCHEMBL3839669 | 0.89 | ALDH1A1 (0.40) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL6046913 | 0.89 | TSHR (0.32) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperidine SCHEMBL30496139 | 0.87 | ALDH1A1 (0.45) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperidine SCHEMBL28253499 | 0.87 | ALDH1A1 (0.45) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Morpholine SCHEMBL9984285 | 0.83 | MEN1 (0.48) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL3733571 | 0.81 | HTR2C (0.33) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL27308161 | 0.80 | TSHR (0.50) | TSHRCYP3A4CA2USP2CA1 | |
| SCHEMBL27346657 | 0.80 | TSHR (0.50) | TSHRCYP3A4CA2USP2CA1 | |
| SCHEMBL5991 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929895-A | Hypoxanthine and xanthine concentration analysis enzymatic compositions as the purine metabolism object for diagnosing tumor | 高普生物有限公司 | 2018-12-04 | — | — | CN | claimed |
| CN-108179173-A | A kind of mycobacterium tuberculosis susceptibility detection color developing agent and its susceptibility detection method | 武汉轻工大学 | 2018-06-19 | — | — | CN | claimed |
| CN-107484643-A | A kind of peony seeds breed breeding culture medium | 安徽省雷氏农业科技有限公司 | 2017-12-19 | — | — | CN | claimed |
| EP-4736255-A2 | SPIROBISINDANE COPOLYMERS AND METHODS OF MAKING | Sepion Technologies, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006736-A9 | SPIROBISINDANE COPOLYMERS AND METHODS OF MAKING | SEPION TECHNOLOGIES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025006736-A2 | SPIROBISINDANE COPOLYMERS AND METHODS OF MAKING | SEPION TECHNOLOGIES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-106676123-B | A kind of screening technique of glucose dehydrogenase mutant | 厦门大学 | 2019-10-22 | — | — | CN | disclosed |
| CN-106323875-B | Sample uses maximized system and method | 西拉诺斯知识产权有限责任公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-109897840-A | Polyphosphoric acid dependent form glucokinase enzyme variants and its application | 中国科学院天津工业生物技术研究所 | 2019-06-18 | — | — | CN | disclosed |
| CN-109689648-A | 2-substituted benzothiazolyl-3-substituted phenyl-5-substituted sulfonated phenyl-2H-tetrazolium salt, reagent for measuring concentration of biological component containing the salt, and method for measuring concentration of biological component using the salt | 泰尔茂株式会社 | 2019-04-26 | — | — | CN | disclosed |
| CN-104619851-B | Method for producing methacrylic acid ester | 三菱化学株式会社 | 2019-03-19 | — | — | CN | disclosed |
| CN-106255692-A | Imidazo [4,5-c ] quinolin-2-one compounds and their use in treating cancer | 阿斯利康(瑞典)有限公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-103649754-B | Assay method | 杜邦营养生物科学有限公司 | 2016-11-02 | — | — | CN | disclosed |
| CN-103842518-B | For the redox reagent compositions of electrochemica biological sensor and comprise the biosensor of described compositions | 爱-森斯株式会社 | 2016-10-12 | — | — | CN | disclosed |
| CN-104427991-A | Peptides derived from HIV GP41 for the treatment of T cell mediated pathologies | YEDA RES & DEV | 2015-03-18 | — | — | CN | disclosed |
| CN-103477197-A | System and method for maximizing sample usage | THERANOS INC | 2013-12-25 | — | — | CN | disclosed |
| CN-101108809-B | 1- (alkylaminoalkyl-pyrrolidine-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists | THERAVANCE INC | 2010-07-14 | — | — | CN | disclosed |
| CN-100406435-C | 1- (alkylaminoalkyl-pyrrolidine-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists | THERAVANCE INC (US) | 2008-07-30 | — | — | CN | disclosed |
| CN-101108809-A | 1- (alkylaminoalkyl-pyrrolidine-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists | THERAVANCE INC (US) | 2008-01-23 | — | — | CN | disclosed |
| CN-1805927-A | 1- (alkylaminoalkyl-pyrrolidine-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists | THERAVANCE INC (US) | 2006-07-19 | — | — | CN | disclosed |